The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: DNA polymerase compositions. Buy the report here.

However, not all innovations are equal nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1 which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

DNA polymerase compositions is a key innovation area in the pharmaceutical industry

DNA polymerases is a member of a family of enzymes that catalyse the synthesis of DNA molecules from nucleoside triphosphates, which are molecular precursors of DNA by the process of replication. These enzymes are essential for DNA replication and usually work in groups to create two identical DNA duplexes from single original duplex. DNA polymerase subunit Pol α initiates DNA synthesis, Pol δ synthesizes the lagging strand, and Pol ε synthesizes the leading strand. The majority of DNA replication is performed by Pol δ and Pol ε.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 100 companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of DNA polymerase compositions.

Key players in DNA polymerase compositions – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to fatty oil extraction

Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies
F. Hoffmann-La Roche 487 Unlock company profile
Thermo Fisher Scientific 286 Unlock company profile
GemVax & KAEL 188 Unlock company profile
Illumina 128 Unlock company profile
Invectys 72 Unlock company profile
New England Biolabs 70 Unlock company profile
Cell Signaling Technology 69 Unlock company profile
Compagnie Merieux Alliance 64 Unlock company profile
Seattle Children's Hospital 61 Unlock company profile
BioRad Laboratories 54 Unlock company profile
Adverum Biotechnologies 48 Unlock company profile
Pacific Biosciences of California 44 Unlock company profile
Spanish National Research Council 40 Unlock company profile
Beijing BGI-GBI Biotech 38 Unlock company profile
NMS Group 38 Unlock company profile
A. Menarini Industrie Farmaceutiche Riunite 37 Unlock company profile
Consejo Superior Investigacion 36 Unlock company profile
Takara Holdings 35 Unlock company profile
Opthea 35 Unlock company profile
City of Hope 34 Unlock company profile
Bio-Rad Laboratories 33 Unlock company profile
Danaher 31 Unlock company profile
OncoPlex Diagnostics 28 Unlock company profile
Toyobo 27 Unlock company profile
Solis BioDyne 27 Unlock company profile
Genecast 25 Unlock company profile
Amgen 25 Unlock company profile
Ultimovacs 24 Unlock company profile
Gilead Sciences 22 Unlock company profile
Ligacept 22 Unlock company profile
UK Research and Innovation 21 Unlock company profile
Astellas Pharma 19 Unlock company profile
Mitsui Chemicals 19 Unlock company profile
Debiopharm Group 19 Unlock company profile
Quantum-Si 18 Unlock company profile
Aravive 17 Unlock company profile
Abbott Laboratories 17 Unlock company profile
Sanofi 17 Unlock company profile
National Cancer Center 17 Unlock company profile
Geron 17 Unlock company profile
Pfizer 16 Unlock company profile
Qiagen 15 Unlock company profile
Oxford Nanopore Technologies 15 Unlock company profile
Twist Bioscience 15 Unlock company profile
Inovio Pharmaceuticals 15 Unlock company profile
TME Pharma 15 Unlock company profile
Viridos 14 Unlock company profile
LifeSci Index Partners 14 Unlock company profile
Algentech 14 Unlock company profile
Precigen 13 Unlock company profile

Source: GlobalData Patent Analytics

F. Hoffmann-La Roche (Roche) is the leading patent filer in DNA polymerase compositions. Roche is an innovative global healthcare company, whose primary focus includes haematology, infectious diseases, neurology, immunology, ophthalmology, rare diseases, respiratory, women’s health, inflammatory bowel diseases, and oncology. Currently, Roche has one marketed DNA polymerase inhibitor drug valganciclovir hydrochloride, Valcyte, for the treatment of Cytomegalovirus (HHV-5) infections. GemVax & KAEL and Invectys are the other key patent filers in DNA polymerase compositions.

In terms of application diversity, Precigen is the top company, followed by Calitor Sciences, and C. H. Boehringer Sohn. By means of geographic reach, the Seattle Children's Hospital held the top position, while Astellas Pharma and Amgen stand in the second and third position, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.